Última actualización 6 de julio de 2026
Key finding
The risk of the primary outcome in the overall trial population was 14% lower for oral semaglutide versus placebo (hazard ratio, 0.86; 95% CI, 0.77–0.96).
This study evaluated the effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes, finding a 14% reduction in major adverse cardiovascular events compared to placebo.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes, finding a 14% reduction in major adverse cardiovascular events compared to placebo.
These findings are clinically significant as they suggest that oral semaglutide not only helps manage blood sugar levels in type 2 diabetes but also may lower the risk of serious cardiovascular events. This dual benefit could lead to better overall health outcomes for patients with diabetes, a population at high risk for heart disease.
The study did not assess long-term cardiovascular outcomes beyond the trial duration. Findings may not be generalizable to all populations with type 2 diabetes. Subgroup analyses did not show significant interactions for several outcomes.
Published in
Publication details and source links for this paper.
Nikolaus M, John ED, Johannes FM, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Circulation. 2025;151(23):1639-1650. doi:10.1161/CIRCULATIONAHA.125.074545
Oral semaglutide reduced the risk of major adverse cardiovascular events by 14%.
Significant reduction in HbA1c levels was observed with oral semaglutide compared to placebo (p=0.05).
Body mass index decreased more with oral semaglutide than with placebo (p=0.05).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Adverse events incidence, All-cause mortality, BMI, and 7 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
6
Related topics
10
Evidence pairs
500
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Relación de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Semaglutide → Adverse events incidence
Semaglutide → Adverse events incidence
Semaglutide → Estimated glomerular filtration rate
Semaglutide → Estimated glomerular filtration rate
Semaglutide → Time to cardiovascular death
Semaglutide → Time to cardiovascular death
Semaglutide → Time to first nonfatal myocardial infarction event
Semaglutide → Time to first nonfatal myocardial infarction event
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Cardiovascular Outcomes.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Cardiovascular Outcomes
Measures Cardiovascular Outcomes as a key outcome.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
12 results
6 results
12 results
12 results
6 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Cardiovascular Outcomes.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
All-cause mortality
EvidenceScore™ Strong | EvidenceScore™ 82.9 | weak positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 11 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 87.5 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Mass Index.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
BMI
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 12 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists appears to improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
LDL cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.